Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
Public ClinicalTrials.gov record NCT00085839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Study of Single Agent Erlotinib [Tarceva (TM), OSI-774] Versus Standard Chemotherapy in Patients With Previously Untreated Advanced NSCLC and a Poor Performance Status
Study identification
- NCT ID
- NCT00085839
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Interventions
- Combination carboplatin and paclitaxel Drug
- Tarceva (Trademark) (erlotinib HCl, OSI-774) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2004
- Primary completion
- Feb 28, 2007
- Completion
- Feb 28, 2007
- Last update posted
- Aug 8, 2012
2004 – 2007
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Cancer Care, Inc. | Greenbrae | California | 94904 | — |
| Sharp Clinical Oncology Research | San Diego | California | 92123 | — |
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Mount Sinai Cancer Center | Miami Beach | Florida | 33140 | — |
| Evanston Northwestern Healthcare | Evanston | Illinois | 60201 | — |
| Oncology/Hematology Associates of Central Illinois | Peoria | Illinois | 61615 | — |
| Norton Healthcare, Inc. | Louisville | Kentucky | 40202 | — |
| Maryland Hematology/Oncology Associates | Baltimore | Maryland | 21237 | — |
| VA Sierra Nevada Health Care System | Reno | Nevada | 89502 | — |
| Weill Medical College of Cornell University | New York | New York | 10021 | — |
| FEK Addo, PC | Bismarck | North Dakota | 58503 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Ohio State University | Columbus | Ohio | 43210-1240 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Charleston Hematology Oncology | Charleston | South Carolina | 29403 | — |
| East Tennessee Oncology/Hematology, PC | Knoxville | Tennessee | 37920 | — |
| Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00085839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 8, 2012 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00085839 live on ClinicalTrials.gov.